Company intelligence / Profile preview

Hyperthermics

Ulsteinvik, Møre og Romsdal, Norwayhyperthermics.com ↗

Ownership: Private
Development stage: Other

Overview

Hyperthermics has demonstrated successful pilot-scale results using hyperthermophilic bacteria to rapidly convert organic waste into biogas and protein. The company is moving toward large-scale commercialization with major partners in the European biogas and aquaculture industries. Recent capital raises support further market entry.

Modalities: Microbial therapy (industrial/bioprocessing use of hyperthermophilic bacteria)
Industry: Non-Drug Biotech

Partnerships

Nature Energy [major Danish/EU biogas producer]Hofseth Aqua [Norwegian aquaculture/fish farming]World Heritage Salmon project [aquaculture initiative]

Beyond the preview

Go deeper on Hyperthermics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hyperthermics.

Explore the full profile